Live
IlluminaWilkins Investment Counsel Inc. Trims Stake in Illumina, Inc. $ILMN - MarketBeatSamsung Biologics(LEAD) Samsung Biologics labor union set to resume talks with management on Monday - Yonhap News AgencyBio-RadBio-Rad expands antibody portfolio for biologics bioanalysis and drug monitoring - Laboratory TalkSamsung BiologicsFirst strikes in Samsung Biologics' 15-year history put labor relations to test - The Korea Herald10x Genomics NewsShould Launch of Atera Spatial Biology Platform Require Action From 10x Genomics (TXG) Investors? - Yahoo Finance UK10x Genomics BlogShould Launch of Atera Spatial Biology Platform Require Action From 10x Genomics (TXG) Investors? - Yahoo FinanceGE HealthCareGE HealthCare Venue Family: How POCUS supports clinicians where they work - gehealthcare.comVertexBank of America Names Vertex Pharmaceuticals Top Biotech Pick for 2026 - HarianBasis.coVertexVertex (VRTX) Named Top Biotech Pick for 2026 by BofA - Yahoo FinanceSamsung BiologicsUnionized workers of Samsung Biologics continue strike for 2nd day - ETHRWorld.comIlluminaAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM) - The Globe and MailCellGenetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells
Roche Media Jan 27, 2026

Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive

Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive

Original
Body unavailable. Use the original source.